tiprankstipranks
Dyne Therapeutics, Inc. (DYN)
NASDAQ:DYN
US Market
DYN
Dyne Therapeutics
RESEARCH TOOLSreports
Want to see DYN full AI Analyst Report?

Dyne Therapeutics (DYN) Stock News & Sentiment

464 Followers
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
Premium
Ratings
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
6d ago
DYN
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
Premium
Ratings
Analyst Maintains Buy Rating on Dyne, Keeps $50 Price Target on Strength of FORZETTO Study Design and Z‑Rostudirsen Data
12d ago
DYN
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
Premium
Ratings
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating
1M ago
DYN
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
Premium
Company Announcements
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1
2M ago
DYN
Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
Premium
Ratings
Buy Rating on Dyne Therapeutics Driven by Robust Phase 3 DM1 Endpoint Strategy and Emerging Disease‑Modification Data
3M ago
DYN
Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference
Premium
Company Announcements
Dyne Therapeutics Highlights Pipeline and Cash at JPM Conference
5M ago
8K
DYN
Dyne Therapeutics Appoints Vikram Karnani to Board
Premium
Company Announcements
Dyne Therapeutics Appoints Vikram Karnani to Board
5M ago
8K
DYN
More DYN News >

DYN News on the Web

Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean | The Motley Fool
Motley Fool
Bullish
Insider Move: Dyne Therapeutics Director Makes Bold New Buy
TipRanks News
Neutral
Dyne Therapeutics To Submit BLA To FDA For Z- Rostudirsen
rttnews
Bullish
Analyst Lifts Dyne Price Target to $47 on Strong DMD Execution, Phase 3 Progress and Expanding Exon-Skipping Pipeline
TipRanks News
Bullish
Dyne Therapeutics announces submission of BLA to U.S. FDA for z-rostudirsen
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN), Kura Oncology (KURA) and 3SBio (OtherTRSBF)
TipRanks News
Bullish
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN)
GuruFocus News
Neutral
Top Dyne Therapeutics Insider Quietly Snaps Up More Shares in Bold Move
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
DYN
Sector Average
Media Buzz
This Week4 articles
Weekly Average7.25 articles
News Sentiment
This Week100%
Sector Average82%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DYN’s Media Buzz Sentiment?
4 articles about DYN were published this week. In an average week, 7.25 articles are published.
    What is DYN’s weekly average amount of articles?
    In an average week, 7.25 articles about DYN are published.
      What is DYN’s News Sentiment?
      100% of articles about DYN were positive this week, compared to its sector average of 82%.
        Healthcare Stocks that are Trending in the News
        AAgilent
        PHRPhreesia
        ADOAnteoTech Ltd
        OTLKOutlook Therapeutics
        IHHHFIHH Healthcare Bhd
        Showing the stocks with the most bullish news sentiment over the past week